Key facts
- Notable investors include Tengye Ventures, Zhongshan Health Base Group, Zhongshan Torch Electronic Industry Fund Management.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Hengdong Shengwu
- ·The full record, as it builds
Funding rounds
No funding rounds for Hengdong Shengwu are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hengdong Shengwu
Developer of agonist antibody drugs intended for tumour targeting. The company offers optimised monoclonal antibodies, bispecific antibody constructs, tumour-targeting mechanisms and agonist activity enhancement technologies, enabling the creation of novel therapeutic candidates for cancer treatment with improved efficacy and intellectual property protection.
- Sector
- Healthcare
- HQ
- Zhongshan, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
Hengdong Shengwu doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hengdong Shengwu shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hengdong Shengwu in its N-PORT filings yet. We sweep new filings monthly.